JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us
Esta página ha sido traducida por una máquina. Otras páginas pueden seguir apareciendo en inglés. View in English

Nuevas promesas y desafíos en el tratamiento del cáncer de pulmón de células no pequeñas avanzado

  • 0Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Health System, New York City, NY, USA.
Lancet +

|

9 de agosto de 2024

|

9 de agosto de 2024

Ver abstracta en PubMed

Resumen

Este resumen es generado por máquina.

Los tratamientos avanzados de cáncer de pulmón no de células pequeñas (CPNPC) han mejorado con terapias dirigidas e inmunoterapias. Los desafíos persisten en la selección de tratamientos personalizados, la resistencia, el costo y la accesibilidad para obtener resultados óptimos para los pacientes.

Área De La Ciencia

  • En el campo de la oncología
  • Farmacología
  • Inmunología

Sus Antecedentes

  • El tratamiento avanzado del cáncer de pulmón de células no pequeñas (CPNPC) ha experimentado un progreso significativo.
  • Las terapias dirigidas y las inmunoterapias son avances clave.

Objetivo Del Estudio

  • Revisar los tratamientos actuales y emergentes para el NSCLC avanzado.
  • Para resaltar los desafíos en la optimización de la terapia NSCLC.

Principales Métodos

  • Revisión de la literatura sobre terapias dirigidas, inmunoterapias y nuevas modalidades de tratamiento.
  • Análisis de las directrices actuales de tratamiento y de las direcciones terapéuticas futuras.

Principales Resultados

  • Los inhibidores de la tirosina quinasa (TKI) evolucionan a través de generaciones para superar la resistencia.
  • Los inhibidores del punto de control inmune (ICI) son cruciales para el NSCLC sin mutaciones procesables.
  • Están surgiendo nuevos agentes como los conjugados anticuerpo-fármaco (ADC), los anticuerpos bispecíficos, los agentes de activación de las células T, las terapias celulares, las vacunas contra el cáncer y los dispositivos externos.

Conclusiones

  • A pesar de los avances, los desafíos en la identificación predictiva de biomarcadores dificultan el tratamiento personalizado.
  • Abordar la resistencia al tratamiento, el costo y la accesibilidad es crucial para mejorar la atención del NSCLC.

Videos de Conceptos Relacionados

Targeted Cancer Therapies 02:57

7.5K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Therapies 02:49

7.6K

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Combination Therapies and Personalized Medicine 02:50

4.9K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

COPD: Pathogenesis and Clinical Features 01:20

248

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Nursing Ethical Principles II 01:27

939

Ethical principles are essential in guiding nurses to fulfill their responsibilities, focusing on the quality of nursing care and decision-making. These principles, including autonomy, beneficence, non-maleficence, justice, and fidelity, shape the ethical framework within healthcare settings.
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...

Treatment Resistant Cancers 02:56

3.3K

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...